NCT05961839CompletedPhase 1
A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 May 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- First submitted
- 3 Oct 2023
- Start date
- 15 Feb 2024
- Lead sponsor
- Schrodinger Inc.
- NCT number
- NCT05961839
- EU CT number
- 2023-507321-42-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 53
- 7 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital San Pedro De Alcántara Coordinator of this site? Confirm its status | Cáceres | Spain | Completed |
| Hospital Universitario 12 de Octubre Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Hospital Universitario Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Hospital Universitario Y Politecnico La Fe Coordinator of this site? Confirm its status | Valencia | Spain | Completed |
| Institut Paoli-Calmettes Coordinator of this site? Confirm its status | Marseille | France | Completed |
| Hopital Saint Louis Coordinator of this site? Confirm its status | Paris | France | Completed |
| Institut Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.